There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vir Biotechnology (VIR – Research Report) and Galera Therapeutics (GRTX – Research Report) with bullish sentiments.
Vir Biotechnology (VIR)
In a report released today, Paul Choi from Goldman Sachs upgraded Vir Biotechnology to Buy, with a price target of $53.00. The company’s shares closed last Friday at $25.74.
According to TipRanks.com, Choi is a 4-star analyst with an average return of 5.8% and a 50.0% success rate. Choi covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Gossamer Bio, and Xenon.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vir Biotechnology with a $56.60 average price target.
Galera Therapeutics (GRTX)
Piper Sandler analyst Edward Tenthoff initiated coverage with a Buy rating on Galera Therapeutics yesterday and set a price target of $6.00. The company’s shares closed last Friday at $1.72.
According to TipRanks.com, Tenthoff is a 5-star analyst with an average return of 18.7% and a 46.6% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Arvinas Holding Company, and Monte Rosa Therapeutics.
Currently, the analyst consensus on Galera Therapeutics is a Strong Buy with an average price target of $10.25, representing a 517.5% upside. In a report issued on February 16, Bank of America Securities also upgraded the stock to Buy with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIR: